Despite recent setbacks in clinical trials, there is still hope for improving treatments for high-risk myelodysplastic syndromes.
David Valcárcel Ferreiras, MD, PhD
David Valcárcel Ferreiras, MD, PhD, is the director, Hematopoietic Stem Cell Transplant Unit University Hospital Vall d'Hebron in Barcelona, Spain.
Articles by David Valcárcel Ferreiras, MD, PhD
Latest Updated Articles
Exploring Advancements in Higher-Risk MDSPublished: September 18th 2024 | Updated: